Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12345678910111213...2425»
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. (Pubmed Central) -  Sep 24, 2022   
    What common features do extant IRTs (i.e., stem cell transplant, alemtuzumab and oral cladribine) have to produce the durable therapeutic response without long term treatment in neuroimmunological diseases such as MS (multiple sclerosis) and NMOSD (neuromyelitis optica spectrum disorders)? Can we learn from these critical features to predict what other maneuvers or agents might effect similar clinical results with equal or greater efficacy and safety?
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Observational data, Journal:  COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD. (Pubmed Central) -  Sep 10, 2022   
    Our findings suggest that patients on rituximab are still at risk of COVID-19 infection after 2 vaccinations and the receipt of a third vaccination may help to prevent infection. Future large scale studies will be required to better delineate the infection risk of different DMTs after the second and subsequent vaccinations.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, IO biomarker:  How to choose initial treatment in multiple sclerosis patients: a case-based approach. (Pubmed Central) -  Aug 22, 2022   
    Strong evidence supports the use of early high efficacy therapy. However, biomarkers, clinical and radiologic prognostic factors, as well as patients' individual issues, should be valued and considered for a personalized treatment decision.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Rituxan (rituximab) / Roche, Lemtrada (alemtuzumab) / Sanofi
    Trial primary completion date:  COMBAT-MS: COMparison Between All immunoTherapies for Multiple Sclerosis. (clinicaltrials.gov) -  Aug 22, 2022   
    P=N/A,  N=3526, Active, not recruiting, 
    Considering the limitations of indirect comparisons, further research is needed to confirm our findings, preferably head-to-head RCTs and large observational studies. Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre. (Pubmed Central) -  Aug 5, 2022   
    The present findings suggest that Alemtuzumab treatment in relapsing-remitting pwMS can improve certain domains of physical function (short distance walking) and cognitive function (processing speed, memory), and furthermore stabilize physiological and physical function along with patient-reported outcomes. TRAb levels measured with commercial automatic methods at the time of a patient being diagnosed with alemtuzumab-induced GD emerged as a novel biomarker for predicting a fluctuating disease phenotype, with an influence on subsequent therapeutic decisions and patients' follow-up.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Ocrevus (ocrelizumab) / Roche, Lemtrada (alemtuzumab) / Sanofi
    Trial completion date, Trial primary completion date:  Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (clinicaltrials.gov) -  Aug 3, 2022   
    P3,  N=100, Recruiting, 
    TRAb levels measured with commercial automatic methods at the time of a patient being diagnosed with alemtuzumab-induced GD emerged as a novel biomarker for predicting a fluctuating disease phenotype, with an influence on subsequent therapeutic decisions and patients' follow-up. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2022 --> Dec 2024
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Ocrevus (ocrelizumab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab. (Pubmed Central) -  Jul 24, 2022   
    Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2022 --> Dec 2024 No abstract available
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Therapeutic choices and disease activity after the end of Cladribine treatment: an Italian multicenter study (CladStop) (G104) -  Jul 23, 2022 - Abstract #ECTRIMS2022ECTRIMS_540;    
    Prior to starting cladribine 35.6% of patients were naive, 25.6% were on dimethyl fumarate and 11.1% on glatiramer acetate...The mean follow-up period following the two years of treatment with cladribine was 19.1 months (range 6-34), during which 74 patients (82.2%) did not start any treatment, 6 patients (6.7%) started ocrelizumab, 3 (3.3%) natalizumab, 3 (3.3%) dimethyl-fumarate, 2 (2.2%) alemtuzumab, 1 (1.1%) ofatumumab and 1 (1.1%) siponimod... Most patients who completed the two-year course of cladribine did not start any treatment in the subsequent 19 months and the decision to start a new treatment was mainly driven by the presence of clinical activity during follow-up.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    High efficacy disease modifying therapies increase the risk of cervical abnormalities in women with Multiple Sclerosis (G106) -  Jul 23, 2022 - Abstract #ECTRIMS2022ECTRIMS_506;    
    The risk of cervical abnormalities was more than three-fold higher in women exposed to high efficacy DMTs than low efficacy DMTs. This finding is vitally important for the safety of women with MS and will have direct clinical implications for primary and secondary prevention strategies including cervical cancer screening frequency and human papillomavirus (HPV) vaccination.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. (Pubmed Central) -  Jul 23, 2022   
    On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations...This review presents an overview of currently available monoclonal antibodies for the treatment of RMS, including their mechanism of action, efficacy and safety profile. Furthermore, we provide practical recommendations for risk management, vaccination, and family planning.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Trial completion date, Trial primary completion date:  TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) -  Jul 19, 2022   
    P=N/A,  N=900, Recruiting, 
    This study provides level 4 evidence that AHSCT in patients previously treated with alemtuzumab, cladribine or rituximab is safe and efficacious. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Thyroid Storm in a Patient With Alemtuzumab Induced Graves' Disease () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2294;    
    Our patient described in this case report showed a treatment challenge which required aggressive therapy beyond the standard use of anti-thyroid medications. To date there are no clear guidelines on how to treat GD secondary to immune reconstitution therapy such as Alemtuzumab.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1593;    
    To date there are no clear guidelines on how to treat GD secondary to immune reconstitution therapy such as Alemtuzumab. This case highlights close thyroid monitoring for patients on Alemtuzumab treatment for Multiple Sclerosis to prevent severe orbitopathy.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Autoimmune storm following alemtuzumab. (Pubmed Central) -  Jul 5, 2022   
    We report a case of a patient with relapsing-remitting multiple sclerosis who developed a refractory immune thrombocytopaenia associated with vasculitis, myelofibrosis and later Guillain-Barré syndrome following alemtuzumab. The medical community should be aware of unusual and unexpected adverse events that may be associated with alemtuzumab, especially when occurring simultaneously in the same patient.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Has the pandemic changed treatment strategy in multiple sclerosis? (Pubmed Central) -  Jun 29, 2022   
    The pandemic coincides with a drop in DMT prescription, most markedly for immunosuppressive high-efficacy treatments, strongly suggesting the pandemic as the causal factor. If and how much this affects long-term outcome is yet to be determined.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. (Pubmed Central) -  Jun 25, 2022   
    Interestingly, promising outcomes were described for patients with secondary progressive MS by some studies, which may be worth taking into account when considering treatment options for patients with active, progressive disease. Of note, a significant proportion of patients develop autoimmune disease following transplantation, with alemtuzumab-containing regimens associated with the highest incidence.